ASCO 2026 Highlights: ctDNA-Guided Atezolizumab in MIBC – IMvigor011 Phase 3 Study Breakthrough
At the 2026 American Society of Clinical Oncology (ASCO) annual meeting, results from the Phase 3 IMvigor011 trial indicated that adjuvant atezolizumab, guided by circulating tumor DNA (ctDNA), failed to ... Read More